NCT03566069View on ClinicalTrials.gov

Intranasal Oxytocin as Enhancer of Psychotherapy Outcomes in Severe Mental Illness

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

June 1, 2018

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Severe Mental Illness
Interventions
DRUG

Intranasal Oxytocin

32IU (16IU\*2) of OT, Sorbitol, Benzyl, alcohol glycerol, distilled water.

OTHER

Intranasal Placebo

32IU (16IU\*2) of Sorbitol, Benzyl, alcohol glycerol.

Trial Locations (1)

Unknown

Shalvata Mental health Center, Hod HaSharon

All Listed Sponsors
lead

Shalvata Mental Health Center

OTHER

NCT03566069 - Intranasal Oxytocin as Enhancer of Psychotherapy Outcomes in Severe Mental Illness | Biotech Hunter | Biotech Hunter